Aortic dissection

• (2023): Dai S+, Front Pharmacol Jun (e-Collection) (17 cases)
• (2017): Oshima Y+, Circulation 135(8), 815-817 (pharmacovigilance / pharmacoepidemiology)

Hypertension

• (2021): Duco MR+, J Oncol Pharm Pract Jan, Online ahead of print60%
• (2015): Thompson LA+, J Oncol Pharm Pract 21(4), 258-67 [REVIEW]
• (2011): Escalante CP+, Cardiol Res Pract May (e-Collection) [REVIEW]

QT interval prolonged / QT prolongation

• (2015): Ghatalia P+, Br J Cancer 112(2), 296-305 [REVIEW]

Gastrointestinal adverse reaction

• (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]

Neutropenia (neutrophils decreased)

• (2019): Lv WW+, Medicine (Baltimore) 98(23), e1580625% [REVIEW]

Glaucoma (includes acute angle-closure glaucoma)

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Intraocular pressure increased

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Ocular adverse effect

• (2025): Li C+, Graefes Arch Clin Exp Ophthalmol Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Ocular erythema

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Subconjunctival hemorrhage

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Vision blurred

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Vitreous floaters / floaters / myodesopsia / myiodesopsia / muscae volitantes

• (2018): Jumper JM+, Clin Ophthalmol 12, 621

Renal failure

• Negative findings
• (2024): Barkmeier AJ, Ophthalmol Retina 8(8), 731-732 (no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept)

Adverse effects / adverse reactions

• (2025): Banerjee M+, Ophthalmol Ther Jun, Online ahead of print [REVIEW]